This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Crandall, C. J. Articles by Greendale, G. A. PubMed PubMed Citation Articles by Crandall, C. J. Articles by Greendale, G. A. Related Collections Early Detection Early Detection: Imaging Clinical Intervention: Biomarkers

Increases in Serum Estrone Sulfate Level Are Associated with Increased Mammographic Density during Menopausal Hormone Therapy

David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California

Requests for reprints: Carolyn J. Crandall, David Geffen School of Medicine, University of California at Los Angeles, 911 Broxton Avenue, 1st Floor, Los Angeles, CA 90024. Phone: 310-794-8069; Fax: 310-794-0732. E-mail: ccrandall{at}mednet.ucla.edu

Background: Menopausal hormone therapy increases mammographic density. We determined whether increases in serum estrone sulfate (E₁S) levels during menopausal hormone therapy predict increased mammographic density.

Methods: We measured percent mammographic density and serum E₁S levels in 428 participants of the Postmenopausal Estrogen/Progestin Interventions study who were randomly assigned to daily conjugated equine estrogen (CEE) 0.625 mg alone, CEE + daily medroxyprogesterone acetate (MPA) 2.5 mg, CEE + cyclical MPA (10 mg days 1-12 per 28-day cycle), or CEE + cyclical micronized progesterone (10 mg days 1-12). Serum E₁S levels were determined by RIA. Information about covariates was determined by annual questionnaire. Using linear regression, we determined the association between change in E₁S level from baseline to 12 months and change in percent mammographic density (by semiquantitative interactive threshold method).

Results: After controlling for baseline mammographic density, age, body mass index, alcohol intake, parity, smoking, ethnicity, physical activity, and age at first pregnancy, mammographic density increased by 1.3% for every 1 ng/mL increase in E₁S level (P < 0.0001). The association between change in E₁S level and change in mammographic density differed by treatment group (greater effect in CEE + cyclical MPA group versus CEE group; P = 0.05). After controlling for treatment group, change in the ratio of E₁S to E₁ was also positively associated with change in mammographic density.

Conclusions: Increases in serum E₁S levels during menopausal hormone therapy are associated with increases in mammographic density. The relative contribution of E₁S and E₁ to stimulation of breast tissue awaits further elucidation. (Cancer Epidemiol Biomarkers Prev 2008;17(7):1674–81)